Skip to content
Screener

Mineralys Therapeutics, Inc. MLYS Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$00.0%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
Tenet Healthcare logo
Tenet HealthcareTHC
Medtronic logo
MedtronicMDT
CorMedix logo
CorMedixCRMD

Other financials

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%
CapEx$15.0K
Free cash flow-$37.9M+43.3%

Valuation

See full
Market cap$2.41B+185%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 5:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001933414-26-000084
Line itemMarch 31, 2026December 31, 2025
Total current liabilities14,71815,113
Commitments and contingencies (Note 4)
Stockholders’ equity:
Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 82,454,950 and 81,536,557 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively88
Additional paid-in capital1,134,6441,103,854
Accumulated deficit(496,508)(457,169)
Total stockholders’ equity638,144646,693
Total liabilities and stockholders’ equity$652,862$661,806

Item 1. Financial Statements

FAQ

What is Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share)?
Mineralys Therapeutics, Inc. (MLYS) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
How has Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share) changed year-over-year?
Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share)?
Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.

Ask your AI about Mineralys Therapeutics, Inc.'s common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude